HOPPS Proposal Would Cut CT, MRI Reimbursement
CMS’s proposed hospital outpatient payments for 2014 would cut reimbursement for CT and MRI studies by 18 percent to 38 percent, according to the ACR.
CMS’s proposed hospital outpatient payments for 2014 would cut reimbursement for CT and MRI studies by 18 percent to 38 percent, according to an ACR analysis.
Under the proposed rule for 2014 changes to the Medicare’s Hospital Outpatient Prospective Payment System (HOPPS), CMS is proposing to use fiscal year 2011 cost data to establish cost centers for CT and MRI. These would be separate from the diagnostic radiology cost center for determining payments for CT and MRI in the inpatient setting, ACR said. This would result in drastic cuts to outpatient payments, and technical payments would fall below the rates in the Physician Fee Schedule, which would set the in-office imaging rates.
The ACR has been meeting with the federal Office of Management and Budget about this issue, requesting it not be included in the HOPPS rule. “However,” the ACR stated, “CMS has chosen to move forward and propose these changes.”
The proposed rule, released July 8, has a 60-day comment period.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
